Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
Objective: to examine the hepatic effectiveness of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) through a head-to-head comparison with glucagon-like peptide-1 receptor agonists (GLP-1RA) or thiazolidinediones (TZD) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Design: this population-based cohort study was conducted using a nationwide healthcare claims database (2014–2022) of Korea. We included individuals with MASLD (aged ≥40 years) who initiated SGLT-2i or comparator drugs (GLP-1RA or TZD). Primary outcome was a composite of hepatic decompensation events, including ascites, oesophageal varices with bleeding, hepatic failure or liver transplant. Liver-cause death and all-cause death were also assessed as secondary outcomes. Cox proportional hazards models were used to estimated HRs with 95% CIs.
Results: after 1:1 propensity score matching, we included 22 550 patients who initiated SGLT-2i and GLP-1RA (median age=57 years, 60% male), and 191 628 patients who initiated SGLT-2i and TZD (median age=57 years, 72% male). Compared with GLP-1RA, SGLT-2i showed a similar risk of hepatic decompensation events (HR 0.93, 95% CI 0.76 to 1.14). Compared with TZD, SGLT-2i demonstrated a reduced risk of hepatic decompensation events (HR 0.77, 95% CI 0.72 to 0.82). As compared with TZD, the results of secondary analyses showed significantly lower hepatic decompensation event risks with SGLT-2i when stratified by sex (male: HR 0.87 (95% CI 0.80–0.94); female: HR 0.62 (95% CI 0.55–0.69)).
Conclusions: in this nationwide cohort study, SGLT-2i was associated with a lower risk of hepatic decompensation events in patients with MASLD compared with TZD, while demonstrating similar effectiveness to GLP-1RA.
DIABETES MELLITUS, FATTY LIVER
Bea, Sungho
b7b8a11e-6f82-4383-957a-c3223931fd07
Bae, Jae Hyun
6a605c25-af98-437d-949f-1f5a158a44d6
Cho, Young Min
eaef9f52-f90f-41f0-bb7c-12335aaeda37
Chang, Yoosoo
db82bb32-e10a-4c23-9e05-6cddfe994bc9
Ryu, Seungho
ddfbdb4c-9de6-4ee9-8998-99dcd3518928
Byrne, Chrisopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Shin, Ju-Young
19bce74c-2aa9-483a-b6d0-67c91eb9bc9b
6 September 2024
Bea, Sungho
b7b8a11e-6f82-4383-957a-c3223931fd07
Bae, Jae Hyun
6a605c25-af98-437d-949f-1f5a158a44d6
Cho, Young Min
eaef9f52-f90f-41f0-bb7c-12335aaeda37
Chang, Yoosoo
db82bb32-e10a-4c23-9e05-6cddfe994bc9
Ryu, Seungho
ddfbdb4c-9de6-4ee9-8998-99dcd3518928
Byrne, Chrisopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Shin, Ju-Young
19bce74c-2aa9-483a-b6d0-67c91eb9bc9b
Bea, Sungho, Bae, Jae Hyun, Cho, Young Min, Chang, Yoosoo, Ryu, Seungho, Byrne, Chrisopher D. and Shin, Ju-Young
(2024)
Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease.
Gut.
(doi:10.1136/gutjnl-2024-332687).
Abstract
Objective: to examine the hepatic effectiveness of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) through a head-to-head comparison with glucagon-like peptide-1 receptor agonists (GLP-1RA) or thiazolidinediones (TZD) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Design: this population-based cohort study was conducted using a nationwide healthcare claims database (2014–2022) of Korea. We included individuals with MASLD (aged ≥40 years) who initiated SGLT-2i or comparator drugs (GLP-1RA or TZD). Primary outcome was a composite of hepatic decompensation events, including ascites, oesophageal varices with bleeding, hepatic failure or liver transplant. Liver-cause death and all-cause death were also assessed as secondary outcomes. Cox proportional hazards models were used to estimated HRs with 95% CIs.
Results: after 1:1 propensity score matching, we included 22 550 patients who initiated SGLT-2i and GLP-1RA (median age=57 years, 60% male), and 191 628 patients who initiated SGLT-2i and TZD (median age=57 years, 72% male). Compared with GLP-1RA, SGLT-2i showed a similar risk of hepatic decompensation events (HR 0.93, 95% CI 0.76 to 1.14). Compared with TZD, SGLT-2i demonstrated a reduced risk of hepatic decompensation events (HR 0.77, 95% CI 0.72 to 0.82). As compared with TZD, the results of secondary analyses showed significantly lower hepatic decompensation event risks with SGLT-2i when stratified by sex (male: HR 0.87 (95% CI 0.80–0.94); female: HR 0.62 (95% CI 0.55–0.69)).
Conclusions: in this nationwide cohort study, SGLT-2i was associated with a lower risk of hepatic decompensation events in patients with MASLD compared with TZD, while demonstrating similar effectiveness to GLP-1RA.
Text
Manuscript_clean
- Accepted Manuscript
Text
Gut_Figures
- Accepted Manuscript
Text
gutjnl-2024-332687.full
- Version of Record
More information
Accepted/In Press date: 21 August 2024
e-pub ahead of print date: 6 September 2024
Published date: 6 September 2024
Additional Information:
Publisher Copyright:
© Author(s) (or their employer(s)) 2024.
Keywords:
DIABETES MELLITUS, FATTY LIVER
Identifiers
Local EPrints ID: 493815
URI: http://eprints.soton.ac.uk/id/eprint/493815
ISSN: 1468-3288
PURE UUID: dc35ca80-de30-4ca5-a3f8-1a437d243b10
Catalogue record
Date deposited: 13 Sep 2024 16:34
Last modified: 23 Nov 2024 02:37
Export record
Altmetrics
Contributors
Author:
Sungho Bea
Author:
Jae Hyun Bae
Author:
Young Min Cho
Author:
Yoosoo Chang
Author:
Seungho Ryu
Author:
Ju-Young Shin
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics